24/7 BIOPHARMA - issue 1 / October 2024

CORDENPHARMA

Conclusion

Obtaining a stable, validatable solid-state chemistry form is a central goal of OSD drug development. For many patient-centric reasons, the need to develop drugs for oral administration will likely continue unabated, despite the barriers presented by complex chemistries and formulations. The earlier those barriers are overcome, the better. Innovators increasingly need to find a good home for API solid state characterisation and bioavailability enhancement in the early stages of development. CordenPharma’s approach to solid-state and bioavailability IP enhancement focuses on several distinct areas of study and evaluation utilising some of the industry’s most advanced analytical technologies, solid-state characterisation methodologies and modern state-of-the art drug product development. We offer the opportunity for innovators to evaluate and characterise their API’s solid-state chemistries step-by-step, up or downstream of the processing chain. Even customers in later stages of development can benefit from a robust understanding of their API’s crystal polymorph and why it is optimal for their specific therapy and application.

Fully-integrated supply, continuous improvement and large investments in six technology platforms across our network help customers span the gaps in development, commercialise their products more efficiently and reach patients faster. With expanded capacity, capabilities, expert teams and cutting-edge technology across Europe and the USA, CordenPharma brings bespoke end-to-end services tailored to support your innovative complex modalities for increased efficiency, faster time to market and better patient outcomes.

Dr. STEPHEN HOULDSWORTH Senior Vice-President of Platform Management & Marketing CordenPharma International

25 TWENTYFOURSEVENBIOPHARMA Issue 1 / October 2024